دورية أكاديمية

Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients.

التفاصيل البيبلوغرافية
العنوان: Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients.
المؤلفون: Dales, Jean-Philippe, Garcia, Stéphane, Meunier-Carpentier, Séverine, Andrac-Meyer, Lucile, Haddad, Olivier, Lavaut, Marie-Noölle, Allasia, Claude, Bonnier, Pascal, Charpin, Colette
المصدر: International Journal of Cancer; Sep2005, Vol. 116 Issue 5, p734-739, 6p
مستخلص: Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor that is involved in tumour growth and metastasis by regulating genes involved in response to hypoxia. HIF-1α protein overexpression has been shown in a variety of human cancers, but only 2 studies have documented the prognostic relevance of HIF-1α expression in breast cancer. The aim of our study was to determine accurately the impact of HIF-1α expression on prognosis in a large series ( n = 745) of unselected patients with invasive breast cancer in terms of overall survival, local recurrence and distant metastasis risk. HIF-1α expression was investigated using immunohistochemical assays on frozen sections, and correlated with patients' outcome (median follow-up = 13.5 years). Univariate (Kaplan-Meier) analysis showed that high levels of HIF-1α expression (cutoff = 10%) significantly correlated with poor overall survival ( p = 0.019). HIF-1α expression correlated with high metastasis risk among the whole group of patients ( p = 0.008). Multivariate analysis (Cox model) showed that the HIF-1α predictive value was independent of other current prognostic indicators. Moreover among node negative ones, HIF-1α expression was also significantly predictive of metastasis risk ( p = 0.03) and of relapse ( p = 0.035). All the data suggest that HIF-1α is associated with a worse prognosis in patients with invasive breast carcinoma. Furthermore HIF-1α immunodetection may be considered as a potential indicator for selecting patients who could benefit from specific therapies interfering with HIF-1α pathway. © 2005 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Cancer is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00207136
DOI:10.1002/ijc.20984